The Anglo-Swedish pharmaceutical AstraZeneca has ensured that, according to a study carried out in Canada, your Vaxzevria vaccine is “highly effective” after one dose to prevent severe COVID cases and hospitalizations caused by Delta and Beta variants.
Protection against Delta variant
According to the study, the AstraZeneca achieves 87% efficacy when faced with hospitalization or death caused by the Delta variant, that it was located for the first time in India, and 90% before the alpha or “Kent”, in reference to the English county where it was detected first.
Protection against Beta variant
The study, which was carried out with 69,533 people who had suffered from the disease between December 2020 and May 2021, has concluded that one dose of the vaccine has 82% protection against “hospitalization or death” caused by the beta / gamma variant of COVID-19, first identified in South Africa.
Protection after a dose of Vaxzevria
The study carried out by the Immunization Research Network of Canada (CIRN) had 40,828 people who had been positive for any of the variants considered “worrisome”, while 28,705 were infected with other variants of the coronavirus.
The analysis warns that the study has been conducted on the efficacy with a single doseas they have not had enough time yet to report on the effectiveness of Vaxzevria after the second dose, although different studies have shown an increase in effectiveness after the second injection.
The executive vice president of R&D of the Anglo-Swedish pharmaceutical company, Mene Pangalos, has highlighted that his company’s vaccine, analyzed with “real world data”, guarantees “a high level of protection” against the “most serious forms” of covid-19, even after a single dose.
–
